Related Experiment Video

Updated: May 8, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
09:19

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens

Published on: December 9, 2022

Survey on the incidence and management of pseudomyxoma peritonei in Japan

Toshiyuki Kitai1, Takayoshi Hirai, Takuji Fujita

  • 1Dept. of Surgery, Kishiwada City Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 30, 2013
PubMed
Abstract

Insights

Pseudomyxoma peritonei (PMP) is rare in Japan, with limited adoption of the Sugarbaker procedure. Complete cytoreduction and intraperitoneal chemotherapy were infrequently achieved in treated cases.

Area of Science:

  • Gastroenterological Surgery
  • Gynecologic Oncology
  • Oncology

Background:

  • Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucinous ascites.
  • Radical cytoreductive surgery and intraperitoneal chemotherapy (Sugarbaker procedure) are standard PMP treatments.
  • Understanding PMP incidence and treatment patterns in Japan is crucial.

Purpose of the Study:

  • To determine the incidence of Pseudomyxoma peritonei (PMP) in Japan.
  • To investigate current therapeutic approaches for PMP in Japanese institutions.

Main Methods:

  • A nationwide survey of 1,084 gastroenterological surgery and gynecology institutions in Japan.
  • Analysis of questionnaire data from 379 institutions regarding PMP cases between 2006 and 2010.
  • Evaluation of surgical and chemotherapeutic interventions and outcomes.

Main Results:

  • The mean incidence of diffuse PMP was 0.78 cases per institution over 5 years.
  • Surgery was performed in 87.2% of diffuse PMP cases, with complete cytoreduction in only 13.4%.
  • Chemotherapy was administered in 51.9% of cases, with intraperitoneal chemotherapy in 32.6% of those treated.

Conclusions:

  • Pseudomyxoma peritonei (PMP) is a rare condition in Japan, consistent with international trends.
  • The Sugarbaker procedure is not widely adopted in Japanese institutions for PMP management.
  • Limited data suggests challenges in achieving complete cytoreduction and optimal intraperitoneal chemotherapy delivery.

Related Concept Videos

Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: